Showing results (191-200 of 279) with videos related to

Sort By:
Pageof 28
Klinische Wochenschrift|August 15, 1980
[Sequential combination chemotherapy with vinblastine/bleomycin and adriamycin/cis-dichlorodiammineplatinum (II) in non-seminomatous testicular cancer. II. Long-term results of a study with 140 patients with retroperitoneal disease (stage II) (author's transl)]M E Scheulen, W Bierbaum, N Niederle, et al.
Acta Haematologica|November 11, 2006
Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemiaL Eisele, L Klein-Hitpass, N Chatzimanolis, et al.
British Journal of Cancer|May 5, 2005
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumoursA Awada, A Hendlisz, T Gil, et al.
Cytometry|January 1, 1994
Improved flow-cytometric detection of low P-glycoprotein expression in leukaemic blasts by histogram subtraction analysisM R Müller, K Lennartz, M R Nowrousian, et al.
British Journal of Haematology|May 1, 1996
BCR rearrangement without juxtaposition of ABL in pre-T acute lymphoblastic leukaemiaA Fosså, R Siebert, C Kasper, et al.
Leukemia|December 1, 1996
Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitroJ K Schröder, C Kirch, M Flasshove, et al.
Anti-Cancer Drugs|October 1, 1995
Activity of N-benzyl-adriamycin-14-valerate (AD198), a new anthracycline derivate, in multidrug resistant human ovarian and breast carcinoma cell linesA Harstrick, U Vanhoefer, N Schleucher, et al.
Experimental Hematology|November 10, 1998
In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive of the response to induction chemotherapyS Kasimir-Bauer, H Ottinger, P Meusers, et al.
Clinical Immunology and Immunopathology|October 1, 1992
Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disordersU B Wandl, M Nagel-Hiemke, D May, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1992
Treatment of high-risk, nonseminomatous testicular cancer with cisplatin, ifosfamide and bleomycin: long-term resultsU B Wandl, K Günzel, R Kath, et al.
Pageof 28